Medicare advisers suggest changes to Alzheimer's drug coverage process; entrepreneurs look to upend the biotech funding model

Taking stock of the drug industry, from the lab to the medicine chest

February 14, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jessica Rinaldi/The Boston Globe STAT+ | Medicare advisers suggest tweaks to coverage process for Alzheimer's drugs Medicare advisers want the program to tweak a process that has been used to restrict access to new Alzheimer's drugs. By Rachel Cohrs STAT+ | With $520 million in hand, two entrepreneurs try to upend the biotech funding model Curie.Bio is giving biotech founders much smaller amounts of money at first and allowing them to maintain ownership stakes longer. By Allison DeAngelis and Matthew Herper Opinion: The X-waiver for buprenorphine prescribing is gone. It's time to spread the word A new law eliminating the X-waiver for prescribing buprenorphine for opioid use disorder won't do much good if no one knows about it. By Beth S. Linas and Benjamin P. Linas PATRICK T. FALLON/AFP via Getty Images Vape maker Elf Bar wants to donate to the American Cancer Society, but it doesn't want tobacco money Popular vape maker Elf Bar wanted to donate to the American Cancer Society. But the group doesn't want the money. By Nicholas Florko

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser